[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  PRISM MarketView [@PrismMarketView](/creator/twitter/PrismMarketView) on x 4687 followers Created: 2025-07-18 11:07:59 UTC Mesoblast (Nasdaq: $MESO) is up XX% premarket after reporting $13.2M in first-quarter sales of Ryoncil, its FDA-approved cell therapy for pediatric SR-aGvHD. With broad U.S. coverage now in place and more transplant centers coming online, the commercial launch is gaining momentum. .@MesoblastNews XXX engagements  **Related Topics** [momentum](/topic/momentum) [$132m](/topic/$132m) [$meso](/topic/$meso) [nasdaq](/topic/nasdaq) [prism](/topic/prism) [Post Link](https://x.com/PrismMarketView/status/1946165047329243640)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
PRISM MarketView @PrismMarketView on x 4687 followers
Created: 2025-07-18 11:07:59 UTC
Mesoblast (Nasdaq: $MESO) is up XX% premarket after reporting $13.2M in first-quarter sales of Ryoncil, its FDA-approved cell therapy for pediatric SR-aGvHD.
With broad U.S. coverage now in place and more transplant centers coming online, the commercial launch is gaining momentum. .@MesoblastNews
XXX engagements
/post/tweet::1946165047329243640